[{"address1": "11711 North Meridian Street", "address2": "Suite 300", "city": "Carmel", "state": "IN", "zip": "46032", "country": "United States", "phone": "(317) 659-0200", "website": "https://mbxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter Kent Hawryluk MBA", "age": 55, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 788300, "exercisedValue": 0, "unexercisedValue": 12366896}, {"maxAge": 1, "name": "Mr. Richard B. Bartram CPA", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 642001, "exercisedValue": 0, "unexercisedValue": 3084960}, {"maxAge": 1, "name": "Dr. Salomon  Azoulay M.D.", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 520512, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Gambino", "title": "Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Graham", "age": 57, "title": "Chief Human Resources Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Dorato DABT, Ph.D.", "title": "Sr. Vice President of Discovery & Non-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chatan  Charan Ph.D.", "title": "Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Hope", "title": "Senior Vice President of Regulatory & Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Moraitis M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1751328000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 13.03, "open": 12.91, "dayLow": 12.325, "dayHigh": 15.92, "regularMarketPreviousClose": 13.03, "regularMarketOpen": 12.91, "regularMarketDayLow": 12.325, "regularMarketDayHigh": 15.92, "payoutRatio": 0.0, "forwardPE": -6.253219, "volume": 934485, "regularMarketVolume": 934485, "averageVolume": 325304, "averageVolume10days": 476160, "averageDailyVolume10Day": 476160, "bid": 11.33, "ask": 18.08, "bidSize": 2, "askSize": 2, "marketCap": 486993504, "fiftyTwoWeekLow": 4.807, "fiftyTwoWeekHigh": 27.5, "fiftyDayAverage": 11.9765, "twoHundredDayAverage": 13.820725, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 246337088, "profitMargins": 0.0, "floatShares": 13610404, "sharesOutstanding": 33424400, "sharesShort": 4782900, "sharesShortPriorMonth": 4652881, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.14310001, "heldPercentInsiders": 0.03115, "heldPercentInstitutions": 1.06596, "shortRatio": 12.35, "shortPercentOfFloat": 0.2877, "impliedSharesOutstanding": 33424400, "bookValue": 7.043, "priceToBook": 2.0687206, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -73465000, "trailingEps": -2.2, "forwardEps": -2.33, "enterpriseToEbitda": -3.036, "52WeekChange": -0.38393235, "SandP52WeekChange": 0.16932249, "quoteType": "EQUITY", "currentPrice": 14.57, "targetHighPrice": 44.0, "targetLowPrice": 30.0, "targetMeanPrice": 37.5, "targetMedianPrice": 38.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 240786000, "totalCashPerShare": 7.204, "ebitda": -81136000, "totalDebt": 130000, "quickRatio": 23.106, "currentRatio": 23.307, "debtToEquity": 0.055, "returnOnAssets": -0.31677, "returnOnEquity": -0.48216, "freeCashflow": -42097624, "operatingCashflow": -66649000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MBX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "MBX Biosciences, Inc.", "corporateActions": [], "postMarketTime": 1753486188, "regularMarketTime": 1753473601, "exchange": "NMS", "messageBoardId": "finmb_613097171", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 11.8189, "regularMarketPrice": 14.57, "longName": "MBX Biosciences, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1726234200000, "marketState": "CLOSED", "postMarketChangePercent": 5.35347, "postMarketPrice": 15.35, "postMarketChange": 0.780001, "regularMarketChange": 1.54, "regularMarketDayRange": "12.325 - 15.92", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 325304, "fiftyTwoWeekLowChange": 9.763, "fiftyTwoWeekLowChangePercent": 2.0309963, "fiftyTwoWeekRange": "4.807 - 27.5", "fiftyTwoWeekHighChange": -12.93, "fiftyTwoWeekHighChangePercent": -0.47018182, "fiftyTwoWeekChangePercent": -38.393234, "earningsTimestamp": 1747051200, "earningsTimestampStart": 1754569800, "earningsTimestampEnd": 1754569800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.2, "epsForward": -2.33, "epsCurrentYear": -2.67222, "priceEpsCurrentYear": -5.4523954, "fiftyDayAverageChange": 2.5935001, "fiftyDayAverageChangePercent": 0.2165491, "twoHundredDayAverageChange": 0.74927425, "twoHundredDayAverageChangePercent": 0.054213814, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-09-13", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "MBX Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-07-26"}]